Heartflow to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026

Heartflow, Inc. (Nasdaq: HTFL), a pioneer in AI technology for managing coronary artery disease (CAD), is set to announce its fourth quarter and full-year financial results for 2025 on March 18, 2026, after market close. The announcement will be followed by a conference call at 1:30 PM PT / 4:30 PM ET, where management will discuss the results and take questions from participants. Interested parties can register online to receive dial-in details and are encouraged to do so at least 15 minutes prior to the call. Additionally, a live and archived webcast of the presentation will be accessible on the Investor Relations section of the Heartflow website for 12 months after the event.

Heartflow’s innovative technology utilizes clinically-proven AI and a vast coronary imaging dataset to enhance cardiovascular care. The company’s solutions have been implemented in over 1,400 medical institutions worldwide, allowing for the rapid and accurate diagnosis and management of CAD among diverse patient populations. The company’s AI models are backed by ACC/AHA guidelines and supported by over 600 peer-reviewed studies. Key offerings include a proprietary data pipeline developed from over 160 million annotated CT angiography images, ensuring high accuracy and reproducibility in clinical practice, with acceptance rates exceeding 97%.

Heartflow's advancements have established it as a leader in the field, transforming CAD—from the world’s leading cause of death—into a manageable condition. The Heartflow One platform generates personalized 3D heart models from coronary CTA images, delivering actionable insights without invasive procedures. As Heartflow continues to innovate and expand its footprint in the cardiovascular landscape, it remains committed to improving patient outcomes through early detection and precise management of heart disease.

As Heartflow, Inc. (Nasdaq: HTFL) prepares to report its fourth-quarter and full-year financial results for 2025 on March 18, 2026, investors should remain focused on several key metrics that might influence stock performance post-announcement. Given Heartflow’s established position as a leader in AI technology for coronary artery disease (CAD), the market will be closely watching financial figures, particularly revenue growth and adoption rates of the Heartflow One platform.

Analyst expectations should be anchored in prior quarterly trends, where Heartflow reported growing revenues and expanded institutional adoption. With more than 1,400 institutions integrating their technology globally, any significant gain in market penetration should be viewed positively. Analysts might anticipate an uptick in revenues attributable to increased procedural volumes and an expanded user base, especially as awareness of non-invasive cardiac imaging grows.

Another crucial aspect to watch is Heartflow’s investment in R&D, especially as the competitive landscape in the cardiovascular space intensifies. Robust investment in technology development and validation can enhance Heartflow’s market leadership, potentially resulting in further clinical endorsements and upcoming partnerships.

Investors should also consider regulatory progress, particularly in securing reimbursement codes that could bolster their platform’s adoption. Heartflow’s successful navigation of these factors could present upward momentum in the stock price after the earnings call.

Given the historical performance and the trajectory of adoption within the medical community, a cautious yet optimistic approach may be advisable. If financial results align with or exceed expectations, coupled with strong forward guidance, Heartflow’s stocks could witness a surge. Conversely, any disappointing metrics or cautious forward guidance may lead to volatility. Therefore, stakeholders should prepare for potential market reactions by closely monitoring the upcoming earnings call and reviewing management’s commentary on future prospects.